NHSA Proposes Regulations to Standardize Oral Implant Charges and Reduce Costs
The National Healthcare Security Administration (NHSA) has released a draft proposal titled “Notice on Carrying...
Ping An Good Doctor Reports 2022 Interim Results with Revenue Decline and User Growth
China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as PingAn Good...
WuXi STA Breaks Ground on New US Manufacturing Site in Delaware
WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has announced the commencement...
ZhenGe Biotech Secures RMB 100 Million in Series C+ Funding for CDMO Expansion
China-based Contract Development and Manufacturing Organization (CDMO) ZhenGe Biotech has reportedly raised RMB 100 million...
Henlius Pharma’s 2022 Interim Revenue Jumps 103.5% on Biosimilar Sales and Licensing
Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) reported RMB 1.29 billion (USD 189.4 million) in...
LongBio Pharma Raises Series A+ Funding to Advance Autoimmune Disease Drug Development
LongBio Pharma, a Shanghai-based next-generation macromolecular antibody developer, has raised tens of millions of renminbi...
Fosun Kite’s Yescarta CAR-T Therapy Secures New Clinical Trial Approval in China
Fosun Kite Biotechnology Co., Ltd, a joint venture between Shanghai Fosun Pharmaceutical (Group) Co., Ltd...
mProbe Raises Funds in Series B1 Round Led by AstraZeneca and CICC
Zhejiang-based mProbe, a protein and metabolomic marker discovery technology-based platform company, has reportedly raised an...
Huahai Pharma to Manufacture Pfizer’s Paxlovid for China Market
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has entered into a manufacturing and supply...
Recbio Completes Phase II Trial Enrollment for ReCOV COVID-19 Vaccine
China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced the completion of enrollment...
Healsun Biopharm Raises USD 36.7 Million in Series B Financing for Antibody CDMO Expansion
China-based Hangzhou Healsun Biopharm Co., Ltd, an antibody and recombinant Contract Development and Manufacturing Organization...
Sirnaomics Initiates Phase I/II Trial for STP705 in Facial Squamous Cell Carcinoma
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) announced the first subject systemic dosing in...
NHC, NDRC Issue Guidelines to Boost China’s Birth Rates with Reproductive Support Measures
The National Health Commission (NHC) and National Development and Reform Commission (NDRC), along with multiple...
Biocytogen Pharmaceuticals Makes HKSE Debut with USD 70 Million IPO
Sino-US contract research organization (CRO) Biocytogen Pharmaceuticals (Beijing) Co., Ltd has completed an initial public...
CSPC Pharmaceutical’s Mitoxantrone Liposome Approved for NMOSD Clinical Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its mitoxantrone hydrochloride liposome has received...
Jemincare Licenses Oral Androgen Receptor Degrader to Roche’s Genentech
China-based Jiangxi Jemincare Group has entered into a licensing agreement with Swiss giant Roche’s Genentech....
Spinraza’s NRDL Inclusion Boosts SMA Patient Treatment in China
The Meier Advocacy & Support Center for Spinal Muscular Atrophy (SMA) and the Shenzhen Research...
CDE Releases Draft Guidelines for RWE-Backed Drug Registration Applications
The Center for Drug Evaluation (CDE) has released a notification regarding the “Real-World Evidence (RWE)-backed...
ICT’s GCC19CART Enters US Phase I Study for Colorectal Cancer
Sino-US firm Innovative Cellular Therapeutics (ICT) announced the involvement of the first subject in a...